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Summary
Objectives: The present study sought to investigate the echocardiographic features
of hypertrophic cardiomyopathy (HCM) with mild left ventricular (LV) remodeling,
particularly in relation to wall motion abnormalities.
Methods: Among the 137 consecutive patients with HCM, 13 patients (mean age
52± 13 years) who progressed to mild LV systolic dysfunction (LV ejection fraction
(LVEF) of 35—50%) were studied. By reviewing the echocardiograms of these patients,
wall motion score index (WMSI) was scored using 16 segments model.
Results: HCM patients with mild LV systolic dysfunction exhibited mild LV dilata-
tion, mild left atrial dilatation, septal hypertrophy, and LV wall motion impairment
localized in the septal and apical regions (septal WMSI 1.94± 0.33 vs. total WMSI
1.51± 0.25 and posterior WMSI 1.02± 0.07; p < 0.001). During follow-up, further
deterioration of LV systolic function (LVEF < 35%) was noted in ﬁve patients, who
had less severe hypertrophy at the initial echocardiograms. These patients devel-
oped progressive LV cavity enlargement and more severe and extensive wall motion
abnormalities, accompanied by septal akinesis and wall thinning, although postero-
lateral wall motion impairment was relatively mild (posterior WMSI 1.80± 0.27 vs.
septal WMSI 2.95± 0.11; p < 0.001).
Conclusions: Septal and apical wall motions are reduced in HCM with mild LV remod-
eling. As LV dysfunction pr
LV cavity enlargement beco
impairment is relatively mi
© 2008 Japanese College o
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oi:10.1016/j.jjcc.2008.01.003ogresses, septal akinesis and wall thinning develop and
mes more prominent, though posterolateral wall motion
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Introduction
Although hypertrophic cardiomyopathy (HCM) is
characterized by a hypertrophied nondilated left
ventricle with normal systolic function, a small
subset of HCM patients evolve into so-called ‘end-
stage’ phase with left ventricular (LV) systolic
dysfunction, usually associated with wall thinning
and cavity enlargement [1—4]. These morpho-
logic features of end-stage HCM were previously
reported to be similar to those of dilated cardiomy-
opathy (DCM) [5,6]. However, pathologic studies
suggest characteristic features of end-stage HCM
with extensive transmural scarring in the ventric-
ular septum, distinct from those of DCM [7—10].
Moreover, DCM-like features may be manifest only
after LV remodeling is severe enough to be accom-
panied by diffuse wall thinning. On the contrary,
echocardiographic characteristics of HCM with ear-
lier stage of LV remodeling, that is, mild LV systolic
dysfunction in the course of transition from typi-
cal HCM to DCM-like morphology, are incompletely
understood.
We therefore investigated the echocardiographic
features of HCM with mild LV systolic dysfunction,
with particular focus on the earlier stage of LV
remodeling, and also aimed to elucidate its rela-
tionship to LV wall motion abnormalities.
Methods
Patient selection
Among the 137 consecutive patients with HCM
diagnosed at Kochi Medical School between Jan-
uary 1983 and June 2001 (95 males, 42 females;
mean age 52± 13 years; age range 9—79 years),
15 patients evolved into LV systolic dysfunction.
Four of the 15 patients already had LV systolic dys-
function at diagnosis, and 11 patients developed
LV systolic dysfunction during follow-up. Thirteen
of these 15 patients who had mild LV systolic
dysfunction, that is, LV ejection fraction (EF) of
35—50% at rest by two-dimensional echocardiog-
raphy, consisted of the present study. In order to
focus on the echocardiographic features of ear-
lier stage LV remodeling, one patient with severe
LV systolic dysfunction at initial diagnosis was
excluded from the present study. Another patient
with inadequate echocardiographic image quality
was also excluded. Precise clinical and echocar-
diographic features of the whole HCM cohort
have been already reported [11]. The diagno-
sis of HCM was based on the two-dimensional
echocardiographic demonstration of unexplained LV
m
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ypertrophy (maximal wall thickness≥ 15mm) in
he absence of other cardiac or systemic diseases
apable of producing the magnitude of hypertro-
hy evident (e.g. hypertension or aortic stenosis)
1]. The echocardiograms of 13 patients were com-
ared with those of 50 consecutive patients who
ere recently diagnosed as HCM without LV sys-
olic dysfunction in our institution. Normal values
f echocardiographic measurements were obtained
rom 10 normal subjects without cardiovascular dis-
ases.
chocardiographic studies
or the analysis of this study, we used the echocar-
iograms at the time when LV systolic dysfunction
as ﬁrst documented. Transthoracic echocardiog-
aphy was performed using commercially available
ltrasound machines. Echocardiographic images
ere taken with patients in the left lateral decubi-
us position and were stored in the VHS video tape.
D and M-mode echocardiographic measurements
ere carried out according to the guidelines of the
merican Society of Echocardiography [12,13]. LV
nd-diastolic and end-systolic volumes (EDV and
SV, respectively) and LVEF was measured by modi-
ed Simpson’s formula [13]. Left atrial (LA) volume
as calculated using the three orthogonal LA
imensions at ventricular end-systole, as described
lsewhere [14]. The distribution of hypertrophy and
he wall thickness were assessed at end-diastole by
arasternal short-axis views obtained at the tip of
he mitral valve, at the papillary muscle and api-
al levels [15]. The greatest wall thickness at any
ite in the LV wall was regarded as the maximal wall
hickness.
nalysis of LV wall motion
he echocardiograms of HCM patients with mild
V systolic dysfunction were reviewed and LV
all motion abnormalities were assessed using
he 16 segments model for assessment of LV
all motion according to the recommendations of
he American Society of Echocardiography [12].
all motion score (WMS) was scored as follows
Fig. 1): 1 = normal; 2 = hypokinetic; 3 = akinetic;
= dyskinetic. The average value of WMS was cal-
ulated in the total 16 segments as total WMSI,
n the four septal and anteroseptal segments as
eptal WMSI, in the four posterior and lateral seg-
ents as posterior WMSI, and in the four apical
egments as apical WMSI. Judgment of wall motion
bnormalities was based on the agreement of two
ndependent observers.
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mFigure 1 The 16 segments model according to the reco
ollow-up studies
ll the patients were followed at our outpatient
epartment. The most recent echocardiographic
ata were reviewed and the wall motion abnor-
alities were also analyzed using WMS. Patients
hose systolic function progressively deteriorated,
ith LVEF less than 35% in the follow-up echocar-
iograms, were considered as progression group.
he initial and the follow-up echocardiograms were
ompared between the progression group and the
o progression group. Collection of the follow-up
ata was ended at the end of 2006.
tatistical analysis
ata are expressed as the mean value± S.D.
omparison of categorical variables, expressed as
ounts and percentages, was performed using the
isher’s exact test. Comparisons for continuous
ariables were made using the unpaired or paired
tudent’s t-tests when appropriate. A probability
alue of <0.05 was considered signiﬁcant. All statis-
ical calculations were conducted using Stat-View,
ersion 5.0 (SAS Institute Inc., Cary, North Car-
lina).
esultslinical proﬁle and echocardiographic
ndings
able 1 shows the clinical proﬁles and echocar-
iographic data of HCM patients with mild LV
W
m
E
lndations of the American Society of Echocardiography.
ystolic dysfunction, in comparison with those with
reserved LV systolic function. Five patients had
eart failure symptoms of New York Heart Asso-
iation class III or IV. LV size and volumes were
arger in patients with LV systolic dysfunction than
n those with preserved systolic function. How-
ver, the degree of LV dilatation was modest with
eference to normal values. Seven patients with
ild LV systolic dysfunction showed normal LV
ize or only minimal LV dilatation (LV end-diastolic
imension < 55mm). None of the patients had LV
imension greater than 60mm. LA diameter and
olume were not different between the two groups,
ut increased beyond the normal range. LA size
as still dilated when patients with atrial ﬁbril-
ation were excluded (LA diameter 45± 5mm, LA
olume 58± 16ml). All of the 13 patients had sep-
al hypertrophy of some degree (14—25mm), and
ve patients (38%) showed severe LV hypertrophy
ith maximal wall thickness ≥20mm.
all motion analyses
atients with mild LV systolic dysfunction exhib-
ted signiﬁcant higher values of total WMSI, septal
MSI, and apical WMSI than those with pre-
erved systolic dysfunction, suggesting reduced
all motions, especially in septal and apical regions
Table 1). Fig. 2A shows the spatial distribution
f LV wall motion abnormalities in HCM with
ild LV systolic dysfunction (the average value of
MSI in each segment) using the 16 segments of
odel recommended by the American Society of
chocardiography. LV wall motion impairment was
ocalized in the septal and apical regions (average
98 K. Hayato et al.
Table 1 Clinical characteristics and echocardiographic ﬁndings of HCM patients with mild LV systolic dysfunction
LV systolic
dysfunction
(n = 13)
Preserved LV systolic
function (n = 50)
p Value* Normal values
(n = 10)
Age at echocardiography 62± 13 61± 16 ns 56± 18
Rhythm (Sinus rhythm/Af) 10/3 43/7 ns 10/0
NYHA class III or IV 5 (38%) 4(8%) <0.001 0 (0%)
LV end-diastolic dimension (mm) 54± 4 44± 5 <0.001 46± 4
LV end-systolic dimension (mm) 40± 4 26± 5 <0.001 27± 4
LA diameter (mm) 46± 5 44± 7 ns 34± 5
IVS thickness (mm) 16± 3 18± 3 0.049 9± 1
LV posterior wall thickness (mm) 11± 2 11± 2 ns 9± 1
Maximal wall thickness (mm) 18± 4 21± 3 0.003 9± 1
LV end-diastolic volume (ml) 105± 18 73± 21 <0.001 84± 24
LV end-systolic volume (ml) 58± 11 22± 9 <0.001 29± 10
Ejection fraction (%) 45± 2 71± 8 <0.001 66± 5
LA volume (ml) 62± 17 60± 25 ns 33± 12
MR (moderate or severe) 1 (8%) 7 (14%) ns 0 (0%)
WMSI 1.51± 0.25 1.01± 0.03 <0.001
Sep WMSI 1.94± 0.33 1.04± 0.10 <0.001
Ap WMSI 1.83± 0.56 1.01± 0.04 <0.001
Post WMSI 1.02± 0.07 1.01± 0.04 ns
Continuous values are mean± S.D. HCM, hypertrophic cardiomyopathy; LV, left ventricular; Af, atrial ﬁbrillation; NYHA, New York
; MR
ll mo
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nHeart Association; LA, left atrial; IVS, interventricular septum
Sep WMSI, septal wall motion score index; Ap WMSI, apical wa
index. *p Values for the comparisons between HCM patients wi
LV systolic function (n = 50).
WMS≥ 2.0). Septal WMSI was higher than total WMSI
and posterior WMSI (1.94± 0.33 vs. 1.51± 0.25
and 1.02± 0.07; p < 0.001, respectively), suggest-
ing localized septal wall motion impairment in
these patients (Fig. 2B).Progression of LV remodeling
During the follow-up period, ﬁve patients
showed further deterioration of systolic func-
s
p
o
a
Figure 2 (A) The spatial distribution of LV wall motion abno
numbers on the ﬁgure show the mean values of wall motion
motion score ≥2.0 are shown as gray. See Fig. 1. (B) Average
(seg. 1—16), septal segments (seg. 1, 6, 7 and 12: Sep WMSI
segments (seg. 3, 4, 9 and 10: Post WMSI)., mitral regurgitation; WMSI, total wall motion score index;
tion score index; Post WMSI, posterolateral wall motion score
ld LV systolic dysfunction (n = 13) and patients with preserved
ion (LVEF < 35%) (Fig. 3: progression group). Within
year of echocardiographic documentation of
ild LV systolic dysfunction, one patient died
uddenly and another patient died from sepsis.
herefore, their follow-up echocardiograms were
ot available. The other six patients did not show
igniﬁcant progression and were considered as no
rogression group. Table 2 shows the comparison
f clinical variables between the progression group
nd the no progression group. Age and medications
rmalities in HCM with mild LV systolic dysfunction. The
score of each segment. Segments with the average wall
values of wall motion score index (WMSI) in all segments
), apical segments (seg. 13—16: Ap WMSI) and posterior
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Figure 3 Clinical course of HCM patients with mild LV systolic dysfunction. Thirteen HCM patients were diagnosed
as mild LV systolic dysfunction (EF 35—50%). Among these 13 patients, two patients died within one year, six patients
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mid not show signiﬁcant progression, and the other ﬁve
EF < 35%). HCM, hypertrophic cardiomyopathy; LV, left v
ere not signiﬁcantly different. Patients in the
rogression group were followed with longer inter-
als, which did not reach statistical signiﬁcance.
able 3 shows the comparison of echocardiographic
ata and their longitudinal changes between the
wo groups. LV dimensions and EF were not signif-
cantly different between the two groups at the
nitial echocardiograms, in which mild LV systolic
ysfunction was ﬁrst documented. Speciﬁcally,
eptal thickness and maximal wall thickness were
maller and WMSI was greater in the progression
roup.
In the progression group, longitudinal changes
f echocardiographic data showed progressive
V remodeling. LV cavity became progressively
nlarged, accompanied by septal wall thinning,
r
p
p
Table 2 Comparison of clinical variables between the prog
No progression (n
Age at echocardiography 66± 15
Intervals (years) 5.3± 2.4
Rhythm (Sinus rhythm/Af) 5/1
NYHA class III or IV 1 (17%)
Family history of HCM 4 (67%)
Family history of sudden death 1 (17%)
Medication
ACEI/ARB 3 (50%)
Beta-blocker 3 (50%)
Diuretics 4 (67%)
Digitalis 2 (33%)
Continuous values are mean± S.D. Af, atrial ﬁbrillation; NYHA, New
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin reients showed further deterioration of systolic function
cular; EF, ejection fraction; F/U, follow-up.
s systolic function deteriorated. LV hypertrophy
nally disappeared at any site of the LV wall
n four of the ﬁve patients (maximal wall thick-
ess≤ 11mm). Wall motion abnormalities became
ore severe and extensive in the progression
roup (total WMSI 2.48± 0.10), with anterior,
nteroseptal, inferoseptal, inferior and apical
nvolvement (Fig. 4A). Septal and apical wall
otions were markedly reduced, often accom-
anied by wall thinning resembling old anterior
yocardial infarction. However, posterolateral wall
otion impairment was relatively mild (poste-ior WMSI 1.80± 0.27 vs. septal WMSI 2.95± 0.11;
< 0.001) (Fig. 4B).
Fig. 5 shows a representative case that showed
rogressive LV remodeling. This patient initially
ression and the no progression groups
= 6) Progression (n = 5) p Value
58± 10 ns
8.2± 2.5 ns
4/1 ns
2 (40%) ns
4 (80%) ns
3 (60%) ns
3 (60%) ns
2 (40%) ns
2 (40%) ns
1 (20%) ns
York Heart Association; HCM, hypertrophic cardiomyopathy;
ceptor antagonist.
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Table 3 Echocardiographic variables and their longitudinal changes: comparison between the progression and the no progression groups
No progression (n = 6) Progression (n = 5) p Valueb between the
two groups
Initial Follow-up p Valuea Initial Follow-up p Valuea Initial Follow-up
Age at echocardiography 66 ± 15 70 ± 14 0.009 58 ± 10 66 ± 11 0.002 ns ns
LV end-diastolic dimension (mm) 54 ± 5 58 ± 5 ns 53 ± 2 62 ± 6 0.012 ns ns
LV end-systolic dimension (mm) 40 ± 3 43 ± 5 ns 39 ± 3 50 ± 5 0.002 ns 0.044
LA diameter (mm) 47 ± 1 53 ± 9 ns 45 ± 4 50 ± 10 0.030 ns ns
IVS thickness (mm) 17 ± 3 15 ± 1 ns 14 ± 2 9 ± 3 0.030 0.001 0.001
LV posterior wall thickness (mm) 11 ± 2 10 ± 1 ns 12 ± 1 11 ± 1 ns ns ns
Maximal wall thickness (mm) 19 ± 2 17 ± 2 ns 15 ± 1 11 ± 1 0.003 0.002 <0.001
LV end-diastolic volume (ml) 96 ± 18 113 ± 36 ns 109 ± 15 125 ± 12 0.029 ns ns
LV end-systolic volume (ml) 52 ± 11 66 ± 21 ns 59 ± 6 88 ± 12 0.002 ns ns
Ejection fraction (%) 45 ± 2 42 ± 4 ns 45 ± 2 30 ± 4 0.002 ns 0.001
LA volume (ml) 63 ± 19 95 ± 78 ns 64 ± 16 96 ± 30 0.035 ns ns
WMSI 1.35 ± 0.15 1.66 ± 0.15 <0.001 1.70 ± 0.28 2.48 ± 0.10 0.007 0.031 <0.001
Sep WMSI 1.75 ± 0.35 2.08 ± 0.34 0.025 2.15 ± 0.22 2.95 ± 0.11 0.003 ns <0.001
Ap WMSI 1.54 ± 0.29 2.00 ± 0.32 0.048 2.15 ± 0.76 2.70 ± 0.33 ns ns 0.006
Post WMSI 1.00 ± 0.00 1.00 ± 0.00 ns 1.05 ± 0.11 1.80 ± 0.27 0.009 ns <0.001
Values are mean± S.D.
a p Values for the comparisons between the initial and the follow-up echocardiograms, using paired t-tests.
b p Values for the comparisons between the no progression and the progression groups, using unpaired t-tests. Abbreviations are the same as Table 1.
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Figure 4 (A) The spatial distribution of LV wall motion abnormalities and (B) the average values of LV wall motion score
index in the progression group (n = 5). Although septal and apical wall motions were severely reduced, posterolateral
wall motion was relatively maintained. Abbreviations and gray segments are deﬁned in the same way as in Fig. 2.
Figure 5 M-mode echocardiography of a patient who showed progressive LV remodeling. Left: asymmetric septal
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dypertrophy with normal LV wall motion at the initial
ystolic dysfunction at the age of 44 years. Right: septal w
V remodeling. Abbreviations as in Fig. 3.
resented as typical asymmetric septal hypertrophy
ith preserved systolic function, later developed
ild LV remodeling, and ﬁnally evolved into severe
V systolic dysfunction with cavity enlargement and
eptal akinesis. Fig. 6 demonstrates septal wall
hinning in another patient with ‘end-stage’ heart
ailure, resembling old myocardial infarction.iscussion
n the present study, we ﬁrst demonstrated the pro-
ressive LV remodeling process at its earliest stage
r
w
b
nnosis of hypertrophic cardiomyopathy. Middle: mild LV
thinning and LV dilatation in the more advanced stage of
y assessing longitudinal changes of wall motion
bnormalities. In particular, we presented here
chocardiographic characteristics of HCM with mild
V remodeling, that is, mild LV systolic dysfunction
ith no or mild LV dilatation and preserved septal
ypertrophy, before DCM-like features of end-stage
CM are manifested. HCM patients with mild LV
emodeling showed wall motion abnormalities pre-
ominantly involving septal and apical walls. As LV
emodeling progressed to the more advanced stage
ith severe LV systolic dysfunction, LV dilatation
ecame more prominent and akinesis and thin-
ing of septal or apical walls developed, sometimes
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Signiﬁcance of LV remodeling in the HCM
spectrum
Although LVEF is supernormal or preserved in most
cases of HCM, progression to systolic dysfunction
(LVEF < 50%) occurs in 3—15% of patients when
they are followed long enough [3,16—18]. This
subtype of HCM was initially reported in case
reports in the literature and referred as vari-
ous terms such as ‘dilated phase,’ ‘burned-out
phase’, or ‘end-stage’ [4]. We recently reported
that heart-failure death related to ‘end-stage’ is
an important mode of death in the community-
based cohort of HCM patients in Japan [11].
Patients with systolic dysfunction often exhibit
symptomatic deterioration with progressive con-
gestive heart failure, which is often refractory to
medical treatment, and generally convey a poor
prognosis [16—18]. This is in contrast with the
improved prognosis of DCM in the era of advance-
ment of heart failure management [19]. Therefore,
early recognition of LV remodeling and aggres-
sive treatment strategies to prevent progressive
deterioration have substantial clinical relevance in
the management of HCM. In addition, considering
the progressive and malignant nature of end-
stage HCM, implantable cardioverter-deﬁbrillator
implantation or heart transplantation might be con-
sidered in this subset of patients even when systolic
dysfunction and LV dilatation are modest compared
with those of DCM. Although many case reports of
end-stage HCM have been published, clinical inves-
tigations regarding echocardiographic features of
earlier stage of LV remodeling, particularly local-
t
o
l
e‘end-stage’ heart failure. It shows septal wall thinning
al long axis view. Right: apical 4-chamber view.
zation of wall motion abnormalities, have been
carce.
chocardiographic features of HCM with
ild LV remodeling
n the present study, transthoracic echocardiogra-
hy demonstrated regional wall motion abnormal-
ties in HCM with mild LV remodeling, especially
n the septal and apical regions, when LV dilata-
ion is mild and septal hypertrophy is maintained.
hen systolic function is severely reduced, sep-
al and apical wall motions become akinetic,
ften accompanied by wall thinning and scarring,
nd anterior and inferior wall motions are also
everely impaired. However, even in this more
dvanced stage of LV remodeling, posterolateral
all motion impairment may be relatively mild.
hus, wall motion abnormalities of HCM with LV
emodeling are not equally distributed in the LV
all.
Our results are consistent with the pathologic
bservations and the previous studies using other
iagnostic modalities. HCM hearts obtained after
eath or transplantation in congestive heart failure
howed grossly visible scars and myocardial ﬁbro-
is in the ventricular septum or LV free wall in the
bsence of signiﬁcant narrowing of epicardial coro-
ary arteries [8,9]. Waller et al. investigated the
xplanted hearts at the time of cardiac transplan-
ation and reported that nine of the 10 patients
ith dilated HCM had ventricular wall scarring,
hich was more extensive in the ventricular sep-
um than in the free wall [10]. On the contrary,
hey only found grossly visible small scars in 23%
f their patients with idiopathic DCM. These patho-
ogic studies suggest distinct anatomic features of
nd-stage HCM, extensive myocardial scars pre-
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ominantly involving ventricular septum, different
rom those of DCM.
Previous investigations using cardiac magnetic
esonance tissue tagging reported regional myocar-
ial systolic dysfunction especially in the ventric-
lar septum and anterior wall in HCM [20,21].
urthermore, gadolinium hyperenhancement in the
ardiac magnetic resonance study, assumed to
epresent myocardial ﬁbrosis and scarring, was
bserved predominantly in the septum, anterior
all, and the junctions of the IVS and the right
entricular free wall in HCM and associated with
egional and global contractile dysfunction [22,23].
oon et al. reported that this hyperenhancement
as associated with progressive ventricular dilation
nd reduction of wall thickness [24]. Therefore,
all motion abnormalities may well appear initially
nd predominantly in the septal and anterior walls
n HCM with mild LV remodeling, leading to progres-
ive LV dysfunction and myocardial ﬁbrosis.
rogressive LV remodeling
rogressive LV remodeling is another aspect of
CM with LV dysfunction [25]. Though LV cavity
ilatation was mild and wall thinning was not yet
eveloped in patients with mild LV systolic dys-
unction, in the long-term observation ﬁve patients
howed further deterioration of LV systolic function
the progression group). As systolic function dete-
iorated, LV cavity became progressively enlarged,
ssociated with septal wall thinning. Wall motion
bnormalities became more severe and exten-
ive in these patients. On the contrary, other
atients showed rather gradual LV remodeling (the
o progression group). More severe wall motion
mpairment and relatively smaller septal and maxi-
al wall thickness at the initial echocardiograms in
he progression group may be associated with more
rogressive and rapid LV remodeling. However, it
s not clear whether the apparent differences in
he longitudinal changes of LV systolic function,
etween the progression group and the no pro-
ression group, were due to the different duration
f follow-up periods, or the results of the differ-
nt pathologic process of LV remodeling between
he two groups. As gradual deterioration of LV wall
otion was also observed even in those in the no
rogression group, further deterioration of LV sys-
olic function could have been documented if they
ad been followed with much longer follow-up peri-
ds.
A recent multi-center observation including a
elatively large number of HCM patients have
emonstrated heterogeneous pattern of LV remod-
ling in end-stage HCM [16]. LV cavity dilatation
w
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end-diastolic dimension≥ 55mm) was observed in
nly 52% of their patients with LV systolic dys-
unction (EF < 50%) at the most recent evaluation,
nd 23% of the end-stage HCM patients showed
eptal wall thickness ≥20mm, although serial
chocardiographic observations revealed consider-
ble enlargement of the LV chamber over time.
Although several mechanisms leading to myocar-
ial ﬁbrosis and progressive LV remodeling are
uggested in HCM, such as apoptosis or the genetic
usceptibility to end-stage [16,26], one of the
ost important factors is myocardial ischemia
aused either by small-vessel coronary artery dis-
ase or abnormal coronary vasodilator reserve in
he hypertrophied region. Previous studies have
hown abnormal perfusion and decreased coronary
ow reserve in the hearts of patients with HCM,
nd particularly HCM with LV systolic dysfunction
27—29]. These perfusion abnormalities are pre-
ominantly observed in the septal region, and may
recede the progression to congestive heart failure
r evolution of LV systolic dysfunction [29].
linical implications
ur echocardiographic observations of HCM with
ild LV remodeling have several clinical implica-
ions. First, the characteristic echocardiographic
eatures of LV remodeling in HCM demonstrated in
he present study may be useful in the differentia-
ion from idiopathic DCM, in which LV wall motion
mpairment is diffuse or predominantly involved
n posterolateral wall [10,30]. In fact, it happens
hat patients who have been initially considered as
CM prove to have relatives with typical HCM when
ystematic family screening is carried out. Recent
eports suggest that some mutations in the same
ene encoding the cardiac sarcomere proteins, such
s -myosin heavy chain, cardiac myosin-binding
rotein C, cardiac actin, and cardiac troponin T or
ardiac troponin I, can cause either HCM or DCM-
ike phenotype [31—33].
Second, early identiﬁcation of HCM patients in
ransition to end-stage might enable speciﬁc thera-
ies targeted at delaying the progressive LV remod-
ling or prevent cardiovascular deaths. Whether
peciﬁc agents which inhibit renin—angiotensin sys-
em or -blockers will have any beneﬁt remains to
e clariﬁed, augmentation of progressive LV remod-
ling should be one of the targets of management
trategies in this subset of HCM patients. Therefore,
hen an impairment of septal, anterior, or apical
all motion is observed in HCM, special attention
hould be paid to the longitudinal changes of LV
orphology and systolic function in the context of
evelopment of ‘end-stage’ phase.
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Third, it is clinically important to identify those
who will show rapid and progressive LV remodel-
ing, among HCM patients with mild LV remodeling,
in order to select candidates for heart transplan-
tation. Assessment of wall motion abnormalities
and wall thinning would be helpful in this respect,
although prospective studies including larger num-
ber of patients are required in order to clarify this
issue.
Study limitations
The present study has several limitations. First,
the number of patients with mild LV remodeling is
rather small. Nevertheless, we believe that septal
and anterior asynergy is the most common pattern
of wall motion impairment in ‘end-stage’ HCM, as
septal-dominant hypertrophy is most characteristic
of HCM. Second, our study is in itself retrospec-
tive. Hence, follow-up echocardiograms were not
performed annually in all of the patients. Third,
although some HCM-causing mutations were found
and already reported in some patients included
in the present study [25], comprehensive genetic
data regarding major sarcomere proteins are not
yet available. Finally, although WMS is a well-
established method for assessing LV wall motion,
it is rather subjective and therefore has limita-
tions in the detection of subtle wall abnormalities
in the hypertrophied regions, which may have led
to the nearly normal values of WMSI in those with
preserved systolic function. More objective meth-
ods, such as strain imaging or tissue tracking, would
possibly enable us to detect wall motion abnor-
malities in HCM before LV systolic dysfunction is
manifest.
Conclusion
In HCM with mild LV remodeling, septal and apical
wall motions are reduced, when septal hypertro-
phy is fairly preserved and LV dilatation is mild.
Identiﬁcation of this LV remodeling at its early
stage may enable speciﬁc therapies targeted at
possibly delaying the progressive LV remodeling
or prevent HCM-related cardiovascular events. As
LV remodeling progresses, wall motion abnormal-
ities become more severe and extensive, often
accompanied by akinesis and thinning of septal or
apical walls, and LV cavity enlargement becomes
more prominent, though posterolateral wall motion
is relatively maintained. These echocardiographic
features of mild and progressive LV remodeling are
speciﬁc for the process of ‘end-stage’ HCM and dis-
tinct from those observed in DCM.
[K. Hayato et al.
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